Listen: Biotech Firms Set Their Funding Sights High
The arrival of the new year also brings with it, the arrival of new products in the marketplace. Of specific interest this year are several biotech firms that have their funding sights set fairly high. While 2016 and the 1st quarter of 2017 were somewhat bleak for the industry financially speaking, there was a…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
The arrival of the new year also brings with it, the arrival of new products in the marketplace. Of specific interest this year are several biotech firms that have their funding sights set fairly high. While 2016 and the 1st quarter of 2017 were somewhat bleak for the industry financially speaking, there was a definite uptick beginning in the 2nd quarter of 2017. The Redwood City, California firm, ARMO BioSciences is gathering funding for its white-blood cell boosting immunotherapy offering. On the other coast, Cambridge, Massachusetts-based laboratory, Solid, is moving forward with its gene-transfer therapy aimed at Duchenne Muscular Dystrophy. Finally, anti-aging research continues right down the road at resTORbio, in Boston. These 3 biotech companies are aiming to acquire approximately $271 million in capital this year to continue their research and development.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
